Evaluation of Medical Treatment Success in Ectopic Pregnancy with Single Dose Methotrexate: 5 Year Experience

Yıl 2017, , 188 - 192, 01.12.2017

Ahmet Yıldız , Ozan Doğan

https://doi.org/10.5505/kjms.2017.70883

Öz

Aim: The aim of this study was to evaluate the predictive factors of success or failure of treatment of Ectopic Pregnancy with single
dose Methotrexate (MTX).
Material and Method: In this retrospective study, records of 351 patients who were treated for ectopic pregnancy with single dose
of MTX were reviewed during five years. Patients were divided into two groups; the first group or “success group” are the patients
who were successfully treated with MTX. The second group or “failure group” consist the patients who did not respond to the MTX therapy.
Results: Of 351 patients, 240 (68.3%) were successfully treated with single dose MTX. 111 patients (31.7%) required second dose
MTX or a surgery. The mean initial BHCG level was significantly lower in the treatment success group than in the treatment failure
group (1265 mIU/ml versus 5751 mIU/ml, p<0.001). The number of cases with decreasing BHCG level on day 4 was significantly
more in the success group compared to failure group (62.5% and 36.9% respectively, p<0.0001). The success rate was 95% when
the levels were <1000 mIU/ml, 87.5% when the levels were between 1000–1999 mIU/ml and 35.5% when the levels were >5000
mIU/ml.
Conclusion: Medical treatment with single dose systemic MTX may be an acceptable therapeutic option for ectopic pregnancy
and MTX therapy is a safe and effective treatment modality for ectopic pregnancies with a serum BHCG levels below 3000 mIU/ml.

Anahtar Kelimeler

Ectopic pregnancy, methotrexate, medical treatment

Ektopik Gebeliklerde Tek Doz Metotreksat Tedavisinin Etkinliğinin Değerlendirilmesi: 5 Yıllık Deneyim

Öz

Amaç: Bu çalışmada ektopik gebeliklerde tek doz metotreksat tedavisinin başarı ve başarısızlık oranlarını değerlendirmesi amaçlandı. 
Materyal ve Metot: Çalışmada ektopik gebelik tanısı konulup tek doz metotreksat uygulanan 351 hastanın tıbbi kayıtlarının retrospektif olarak incelenmiştir. Hastalar tek doz metotreksat ile başarılı olarak tedavi edilen ve edilemeyen olmak üzere 2 gruba ayrılarak değerlendirilmiştir.
Bulgular: 351 hastanın 240 (%68,3) tek doz MTX ile başarılı olarak tedavi edilmiştir. 111 (%31,7) hasta ikinci bir MTX dozuna ya da
cerrahi tedaviye ihtiyaç duymuştur. Ortalama BHCG seviyeleri tek doz MTX tedavisine başarılı olarak yanıt veren grupta, başarısız olunan gruba göre belirgin olarak düşük saptandı. (1265 mIU/ml-5751 mIU/ml, p<0,001). Tedaviye başarılı olarak yanıt veren grupla başarısız olunan grup arasında 4. gün BHCG seviyelerindeki düşüş oranı arasında istatistiksel olarak anlamlı fark saptandı. (%62,5 ve %36,9 istatiksel anlamlı, p<0,0001). Tek doz MTX tedavisine başarılı yanıt BHCG seviyeleri <1000 olduğunda %95, 1000–1999 arasında %87,5, >5000 olduğunda %35,5 olarak saptandı.
Sonuç: Tek doz MTX uygulamaları ektopik gebeliklerin medikal tedavisinde kabul edilebilir, güvenli ve efektif bir yöntemdir, özellikle BHCG seviyeleri 3000 altında olan hastalarda ilk seçenek olarak düşünülmelidir.

Anahtar Kelimeler

ektopik gebelik, metotreksat, medikal tedavi

Kaynakça

• 1.Cartwright J, Duncan WC, Critchley HD, Horne AW. Serum biomarkers of tubal ectopic pregnancy: current candidates and future possibilities. Reproduct 2009;138:9–22.
• 2. Thia EH, Loi K, Wang JJ, Siow A. Methotrexate treatment for ectopic pregnancy at the KK Women’s and Children’s Hospital, Singapore. Singapore Med J 2009;50:1058.
• 3. Vaswani PR. Predictors of success of medical management of ectopic pregnancy in a tertiary care hospital in United Arab Emirates. J Clin Diagn Res 2014;8: OC04-OC08.
• 4. Alleyassin A, Khademi A, Aghahosseini M, Safdarian L, Badenoosh B et al. Comparison of success rates in the medical management of ectopic pregnancy with single-dose and multiple-dose administration of methotrexate: a prospective, randomized clinical trial. Fertil Steril 2006;85:1661–1666.
• 5. Bachman EA, Barnhar K. Medical management of ectopic pregnancy: A comparison of regimens. Clin Obstet Gynecol 2012;55:440–447.
• 6. Lipscomb GH, McCord M, Stovall TG, Huff G, Portera SG, Ling FW. Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies. N Engl J Med 1999;341:1974–1978.
• 7. Sagiv R, Debby A, Feit H, Cohen-Sacher B, Keidar R. The optimal cut off serum level of human chorionic gonadotropin for efficacy of methotrexate treatment in women with extra uterine pregnancy. Int J Gynaecol Obstet 2012;116(2):101–104.
• 8. Stovall TG, Ling FW, Gray LA. Single-dose methotrexate for treatment of ectopic pregnancy. Obstet Gynecol 1991;77(5):754–757.
• 9. Gamzu R, Almog B, Levin Y, Avni A, Jaffa A, et al. Efficacy of methotrexate treatment in extra uterine pregnancies defined by stable or increasing human chorionic gonadotropin concentrations. Fertil Steril 2002;77(4):761–765.
• 10. Corsan GH, Karacan M, Qasim S, Bohrer MK, Ransom MX et al. Identification of hormonal parameters for successful systemic single-dose methotrexate therapy in ectopic pregnancy. Hum Reprod 1995;10(10):2719–2722.
• 11. Nazac A, Gervaise A, Bouyer J, de Tayrac R, Capella-Allouc S, et al. Predictors of success in methotrexate treatment of women with unruptured tubal pregnancies. Ultrasound Obstet Gynecol 2003;21(2):181–185.
• 12. Nguyen Q, Kapitz M, Downes K, Silva C. Are early human chorionic gonadotropin levels after Methotrexate therapy a predictor of response in ectopic pregnancy? Am J Obstet Gynecol 2010;202:630–635.
• 13. Nowak-Markwitz E, Michalak M, Olejnik M, Spaczynski M. Cut off value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy. Fertil Steril 2009;92(4):1203–1207.
• 14. Lipscomb GH, Bran D, McCord ML, Portera JC, Ling FW. Analysis of three hundred fifteen ectopic pregnancies treated with single-dose methotrexate. Am J Obstet Gynecol 1998;178:1354–8.
• 15. Potter MB, Lepine LA, Jamieson DJ. Predictors of success with methotrexate treatment of tubal ectopic pregnancy at Grady Memorial Hospital. Am J ObstetGynecol 2003;188:1192–4.
• 16. Tawfiq A, Agameya AF, Claman P. Predictors of treatment failure for ectopic pregnancy treated with single-dose methotrexate. Fertil Steril 2000;74:877–80.
• 17. Erdem M, Erdem A, Arslan M, Oc A, Biberoglu K, Gursoy R. Single-dose methotrexate for the treatment of unruptured ectopic pregnancy. Arch Gynecol Obstet 2004;270:201–4.
• 18. Kirk E, Bourne T. The nonsurgical management of ectopic pregnancy. Curr Opin Obstet Gynecol 2006;18(6):587–593. Review
• 19. Cohen A, Bibi G, Almog B, Tsafrir Z, Levin I. Second-dose methotrexate in ectopic pregnancies: the role of beta human chorionic gonadotropin. Fertil Steril 2014;102:1646–1649.
• 20. Potter MB, Lepine LA, Jamieson DJ. Predictors of success with methotrexate treatment of tubal ectopic pregnancy at Grady Memorial Hospital. Am J Obstet Gynecol 2003;188:1192–1194.
• 21. Ustunyurt E, Duran M, Coskun E, Ustunyurt ÖB, Simşek H. Role of initial and day 4 human chorionic gonadotropin levels in predicting the outcome of single-dose methotrexate treatment in women with tubal ectopic pregnancy. Arch Gynecol Obstet 2013;288:1149–1152.
• 22. Skubisz M, Dutton P, Duncan WC, Horne AW, Tong S. Using a decline in serum hCG between days 0–4 to predict ectopic pregnancy treatment success after single dose methotrexate retrospective cohort study. BMC Pregnancy Childbirth 2013;13:30.
• 23. Levin I, Tsafrir Z, Sa’ar N, Lessing J, Avni A, et al. “Watchful waiting” in ectopic pregnancies: a balance between reduced success rates and less methotrexate. Fertil Steril 2011;95(3):1159–1160.
• 24. Kirk E, VAN Calster B, Condous G, Papageorghiou AT, Gevaert O, et al. Ectopic pregnancy: using the hCG ratio to select women for expectant or medical management. Acta Obstet Gynecol Scand 2011;90(3):264–272.
• 25. Baxi A, Kaushal M, Karmalkar H, Sahu P, Kadhi P, et al. Successful expectant management of tubal heterotopic pregnancy. J Hum Reprod Sci 2010;3(2):108–110.
• 26. Lipscomb GH, Givens VM, Meyer NL, Bran D. Comparison of multidose and single-dose methotrexate protocols for the treatment of ectopic pregnancy. Am J Obstet Gynecol 2005;192:1844–1848.
• 27. Barnhart KT, Gosman G, Ashby R, Sammel M. The medical management of ectopic pregnancy: a meta-analysis comparing “single dose” and “multidose” regimens. Obstet Gynecol 2003;101:778–784.